Study of the Arginase Activity and Other Biochemical Parameters in Patients with Coronary Artery Disease in Baghdad Governorate-Iraq

Authors

  • Huda A. Kareem Hussain Department of Chemistry, College of Science, Mustansiriyah University, 10052 Baghdad, IRAQ.
  • Najlaa Qassim Muftin Department of Chemistry, College of Science, Mustansiriyah University, 10052 Baghdad, IRAQ. https://orcid.org/0000-0002-5892-6127
  • Mahmoud Najim Al-jibouri Department of Chemistry, College of Science, Mustansiriyah University, 10052 Baghdad, IRAQ.
  • Gada Ben Salah Department of Pharmacology and Toxicology, Unaizah College of Pharmacy, Qassim University, Unaizah, Qassim 51911, Saudi Arabia https://orcid.org/0000-0002-5886-1968

DOI:

https://doi.org/10.23851/mjs.v34i1.1251

Keywords:

KEYWORDS: Coronary Artery Disease , Arginase , Troponin I , dyslipidemia , hs-CRP

Abstract

The most prevalent form of heart disease and the main cause of death in both developed and developing nations is CAD. It happens when "plaque," or cholesterol or other fatty deposits that accumulate on the inner wall of the artery, narrows or blocks the arteries that deliver blood to the heart. Over time, chest pain might develop as a result of the reduction in blood flow to the heart caused by this plaque accumulation. The study was designed to find if Arginase acts as a biomarker for diagnosing Coronary Artery Disease (CAD). A total of 90 individual samples were included in the present study, the control group consist of 40 healthy individual samples, while the CAD patients were 50 individual samples. Some biochemical parameters such as fasting blood glucose (FBG), troponin I(TnI), high sensitivity C-reactive protein (hs-CRP), lipid profile, lactate dehydrogenase (LDH), and Arginase activity were analyzed. The results of the current study showed no significant differences in the average age of patients (67.00±6.78) when compared with the control group (61.10±6.46), P>0.05. A significant increase Was found in the FBI level, cholesterol, triglycerides, very low-density lipoprotein (VLDL), low-density lipoprotein (LDL), TnI, hs-CRP, LDH, and Arginase activity in the patient's group when compared with the control group. While significant decrease (P<0.05) was revealed in the high-density lipoprotein (HDL) level in CAD patients in comparison to the control group. Also, there was a positive significant correlation between Arginase activity with each age and FBG. As for the ROC operator curve for Arginase, it was found that the area under the curve (AUC) was 0.953 with a sensitivity of 90%, and specificity of 95%. The results in the present study indicate a possible use of Arginase as a diagnostic marker for CAD.

Downloads

Download data is not yet available.

References

Chaudhary P., Kumar R., Verma A. K., Singh D., Yadav V., Chhillar A. K., and Chandra R. (2006). "Synthesis and antimicrobial activity of N-alkyl and N-aryl piperazine derivatives". Bioorganic & medicinal chemistry, 14(6), 1819-1826.‏

CrossRef | PubMed

Rathish I. G., Javed K., Ahmad S., Bano S., Alam M. S., Pillai K. K., and Bagchi V. (2009). "Synthesis and antiinflammatory activity of some new 1, 3, 5-trisubstituted pyrazolines bearing benzene sulfonamide". Bioorganic & medicinal chemistry letters, 19(1), 255-258.‏

CrossRef | PubMed

Bansilal B., Ali N., Afzal N., Khan T. S., and Shahjahan S. (2007). "Antioxidant status in coronary heart disease (CHD) patients with type 2 diabetes mellitus". Journal of Ayub Medical College Abbottabad.

Mamolo M. G., Zampieri D., Falagiani V., Vio L., and Banfi E. (2001). "Synthesis and antimycobacterial activity of 5-aryl-1-isonicotinoyl-3-(pyridin-2-yl)-4, 5-dihydro-1H-pyrazole derivatives". Il Farmaco.

CrossRef

Negi A. S., Kumar J. K., Luqman S., Shanker K., Gupta M. M., Kand hanuja S. P. S. (2008). "Recent advances in plant hepatoprotectives: a chemical and biological profile of some important leads". Medicinal Research Reviews.

CrossRef | PubMed

Clemente G., van Waarde A. F. ,Antunes I., Dömling A.,and H. Elsinga P. (2020)." Arginase as a potential biomarker of disease progression: a molecular imaging perspective". International Journal of Molecular Sciences.

CrossRef

Caldwell R. W., Rodriguez P. C., Toque H. A., Narayanan S. P., and Caldwell R. B. (2018)."Arginase: a multifaceted enzyme important in health and disease". Physiological reviews.

CrossRef | PubMed

Yu H., Yoo P. K., Aguirre C. C., Tsoa R. W., Kern R. M., Grody W. W.,and Iyer R. K. (2003). "Widespread expression of arginase I in mouse tissues: biochemical and physiological implications". Journal of Histochemistry & Cytochemistry.

CrossRef | PubMed

Suman M., and Rajnikant M. (2017). "Mitochondrial membrane-bound activity of arginase is independent of nitrogen excretion pattern in ureogenic and non-ureogenic vertebrates".‏

Shah S. F. A., Khan M. J., Iqbal T., Akram S., Waheed F., Satti H. S., and Hussain S. (2019). "Arginase-1 variants and the risk of familial coronary artery disease in subjects originating from Pakistan". Genetic Testing and Molecular Biomarkers.

CrossRef

Shemyakin A. (2012)."Arginase Inhibition Improves Endothelial Function in Patients with Coronary Artery Disease and Type 2 Diabetes".‏ Circulation.

CrossRef | PubMed

Wernly B., Pernow J., Kelm M., and Jung C. (2020). "The role of arginase in the microcirculation in cardiovascular disease". Clinical Hemorheology and Microcirculation.

CrossRef | PubMed

Bekpinar S., Gurdol F., Unlucerci Y., Develi S., and Yilmaz A. (2011). "Serum levels of arginase I are associated with left ventricular function after myocardial infarction". Clinical biochemistry.

CrossRef | PubMed

Porembska Z.,and Kedra M. (1975). "Early diagnosis of myocardial infarction by arginase activity determination". Clinica Chimica Acta.

CrossRef | PubMed

Porembska, Z., & Kedra, M. (1975). "Early diagnosis of myocardial infarction by Arginase activity determination".Clinica Chimica Acta.

CrossRef | PubMed

Kövamees O., Shemyakin A., and Pernow J. (2016). "Amino acid metabolism reflecting arginase activity is increased in patients with type 2 diabetes and associated with endothelial dysfunction". Diabetes and vascular disease research.

CrossRef | PubMed

Ryoo S., Bhunia A., Chang F., Shoukas A., Berkowitz D. E., and Romer L. H. (2011). "OxLDL-dependent activation of arginase II is dependent on the LOX-1 receptor and downstream RhoA signaling". Atherosclerosis.

CrossRef | PubMed

Zhang R., Ji, Z., Qu Y., Yang M., Su Y., Zuo W., and Li Y. (2020)." Clinical value of ARG1 in acute myocardial infarction patients: Bioinformatics-based approach". Biomedicine & Pharmacotherapy.

CrossRef | PubMed

Sharma S. B., Garg S., Veerwal A.,and Dwivedi S. (2008)."hs-CRP and oxidative stress in young CAD patients: a pilot study". Indian journal of clinical biochemistry.

CrossRef

Khaki K. F., Yaghoubi A. R., Zarghami N., and Rahbani M. (2011). "Evaluation of hs-CRP, antioxidant markers and MDA in patients of Coronary Artery Disease (CAD) containing Non-Smokers and Non-Diabetics". Clinical Biochemistry.

CrossRef

Arroyo-Espliguero R., Avanzas P., Cosín-Sales J., Aldama G., Pizzi C., and Kaski J. C. (2004). "C-reactive protein elevation and disease activity in patients with coronary artery disease". European heart journal.

CrossRef | PubMed

Khatibi F. K., Yaghoubi A., Zarghami N., Rahbani M., and Babaie H. (2013). "Evaluation of hs-CRP, Antioxidant Markers andMDA in Patients of Coronary Artery Disease (CAD) Containing Non-Smokers and Non-Diabetics". Journal of Cardiovascular and Thoracic Research.

Jia Y., Wen W., Yang Y., Huang M., Ning Y., Jiao X., and Zhang M. (2021). "The clinical role of combined serum C1q and hsCRP in predicting coronary artery disease". Clinical Biochemistry.

CrossRef

Romero M. J., Platt D. H., Tawfik H. E., Labazi M., El-Remessy A. B., Bartoli M., and Caldwell R. W. (2008)."Diabetes-induced coronary vascular dysfunction involves increased arginase activity". Circulation research.

CrossRef | PubMed

Zhou Z., Mahdi A., Tratsiakovich Y., Zahorán S., Kövamees O., Nordin F., and Pernow J. (2018). "Erythrocytes from patients with type 2 diabetes induce endothelial dysfunction via arginase I". Journal of the American College of Cardiology.

CrossRef

Kim J. H., Bugaj L. J., Oh Y. J., Bivalacqua T. J., Ryoo S., Soucy K. G., and Berkowitz D. E. (2009)."Arginase inhibition restores NOS coupling and reverses endothelial dysfunction and vascular stiffness in old rats". Journal of applied physiology.

CrossRef

Jung C., Grün K., Betge S., Pernow J., Kelm M., Muessig J.,and Franz M. (2017)."Arginase inhibition reverses monocrotaline-induced pulmonary hypertension". International Journal of Molecular Sciences.

CrossRef

Ren B., Van Kampen E., Van Berkel T. J., Cruickshank S. M., and Van Eck M. (2017). "Hematopoietic arginase 1 deficiency results in decreased leukocytosis and increased foam cell formation but does not affect atherosclerosis". Atherosclerosis, 256, 35-46.‏

CrossRef | PubMed

Pourcet B., and Pineda-Torra I. (2013). "Transcriptional regulation of macrophage arginase 1 expression and its role in atherosclerosis". Trends in cardiovascular medicine, 23(5), 143-152.

CrossRef | PubMed

Malakar A. K., Choudhury D., Halder B., Paul P., Uddin A., and Chakraborty S. (2019)." A review on coronary artery disease, its risk factors, and therapeutics". Journal of cellular physiology.

CrossRef | PubMed

Quitter F., Figulla H. R., Ferrari M., Pernow J., and Jung C. (2013). "Increased arginase levels in heart failure represent a therapeutic target to rescue microvascular perfusion". Clinical hemorheology and microcirculation.

CrossRef | PubMed

Shah S. F. A., Iqbal T., Qamar R., Rafiq M. A., and Hussain S. (2018). "ARG1 gene polymorphisms and their association in individuals with essential hypertension: a case-control study". DNA and Cell Biology.

CrossRef | PubMed

Zhao X., Wang D., and Qin L. (2021). "Lipid profile and prognosis in patients with coronary heart disease: a meta-analysis of prospective cohort studies". BMC cardiovascular disorders. Disord.

CrossRef

Ramirez A., and Hu P. P. (2015)."Low high-density lipoprotein and risk of myocardial infarction". Clinical Medicine Insights: Cardiology.

CrossRef | PubMed

Arora S., Qamar A., Gupta P., Vaduganathan M., Chauhan I., Tripathi A. K., and Gupta M. D. (2019). "Design and rationale of the North Indian ST‐Segment Elevation Myocardial Infarction Registry: A prospective cohort study". Clinical cardiology.

CrossRef

Venkateshwarlu M.,and Gayathri C. (2015)."Study of significance of estimation of lipid profile in patient with acute myocardial infarction". Int J Inf Res Rev.

Kopel E., Kivity S., Morag-Koren N., Segev S., and Sidi Y. (2012)."Relation of serum lactate dehydrogenase to coronary artery disease". The American journal of cardiology.

CrossRef | PubMed

Downloads

Key Dates

Published

30-03-2023

Issue

Section

Original Article

How to Cite

[1]
H. A. K. . Hussain, N. Q. . Muftin, M. N. . . Al-jibouri, and G. Ben Salah, “Study of the Arginase Activity and Other Biochemical Parameters in Patients with Coronary Artery Disease in Baghdad Governorate-Iraq”, Al-Mustansiriyah J. Sci., vol. 34, no. 1, pp. 37–44, Mar. 2023, doi: 10.23851/mjs.v34i1.1251.

Similar Articles

11-20 of 44

You may also start an advanced similarity search for this article.